| Carbon nanotubes with DNA recognition KA Williams, PTM Veenhuizen, BG de la Torre, R Eritja, C Dekker Nature 420 (6917), 761-761, 2002 | 703 | 2002 |
| The pharmaceutical industry in 2018. An analysis of FDA drug approvals from the perspective of molecules B G de la Torre, F Albericio Molecules 24 (4), 809, 2019 | 259* | 2019 |
| Green solid-phase peptide synthesis 2. 2-Methyltetrahydrofuran and ethyl acetate for solid-phase peptide synthesis under green conditions YE Jad, GA Acosta, T Govender, HG Kruger, A El-Faham, BG de la Torre, ... ACS Sustainable Chemistry & Engineering 4 (12), 6809-6814, 2016 | 183* | 2016 |
| The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules BG de la Torre, F Albericio Molecules 25 (3), 745, 2020 | 180 | 2020 |
| The pharmaceutical industry in 2018. An analysis of FDA drug approvals from the perspective of molecules B G de la Torre, F Albericio Molecules 24 (4), 809, 2019 | 161 | 2019 |
| Peptide Therapeutics 2.0 BG de la Torre, F Albericio Molecules 25 (10), 2293, 2020 | 144 | 2020 |
| Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide C Cubillos, BG de la Torre, A Jakab, G Clementi, E Borrás, J Bárcena, ... Journal of virology 82 (14), 7223-7230, 2008 | 139 | 2008 |
| Linkers: an assurance for controlled delivery of antibody-drug conjugate R Sheyi, BG de la Torre, F Albericio Pharmaceutics 14 (2), 396, 2022 | 132 | 2022 |
| Greening Fmoc/t Bu solid-phase peptide synthesis O Al Musaimi, BG de la Torre, F Albericio Green Chemistry 22 (4), 996-1018, 2020 | 124 | 2020 |
| 2020 FDA TIDES (peptides and oligonucleotides) harvest O Al Musaimi, D Al Shaer, F Albericio, BG de la Torre Pharmaceuticals 14 (2), 145, 2021 | 119 | 2021 |
| Activity of Cecropin A-Melittin Hybrid Peptides against Colistin-Resistant Clinical Strains of Acinetobacter baumannii: Molecular Basis for the Differential … JM Saugar, MJ Rodríguez-Hernández, BG de la Torre, ... Antimicrobial agents and chemotherapy 50 (4), 1251-1256, 2006 | 118 | 2006 |
| Synthesis and biological evaluation of a teixobactin analogue YE Jad, GA Acosta, T Naicker, M Ramtahal, A El-Faham, T Govender, ... Organic letters 17 (24), 6182-6185, 2015 | 111 | 2015 |
| Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences BG de la Torre, F Albericio, E Saison-Behmoaras, A Bachi, R Eritja Bioconjugate chemistry 10 (6), 1005-1012, 1999 | 105 | 1999 |
| Peptide synthesis beyond DMF: THF and ACN as excellent and friendlier alternatives YE Jad, GA Acosta, SN Khattab, BG de la Torre, T Govender, HG Kruger, ... Organic & Biomolecular Chemistry 13 (8), 2393-2398, 2015 | 100 | 2015 |
| Breaking a couple: disulfide reducing agents SN Mthembu, A Sharma, F Albericio, BG de la Torre ChemBioChem 21 (14), 1947-1954, 2020 | 99 | 2020 |
| Stepwise solid-phase synthesis of oligonucleotide-peptide hybrids BG de la Torre, A Aviñó, G Tarrason, J Piulats, F Albericio, R Eritja Tetrahedron Letters 35 (17), 2733-2736, 1994 | 97 | 1994 |
| 2019 FDA TIDES (peptides and oligonucleotides) harvest D Al Shaer, O Al Musaimi, F Albericio, BG de la Torre Pharmaceuticals 13 (3), 40, 2020 | 95* | 2020 |
| Short AntiMicrobial Peptides (SAMPs) as a class of extraordinary promising therapeutic agents S Ramesh, T Govender, HG Kruger, BG de la Torre, F Albericio Journal of Peptide Science 22 (7), 438-451, 2016 | 95 | 2016 |
| Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment M Torrent, BG de La Torre, VM Nogués, D Andreu, E Boix Biochemical Journal 421 (3), 425-434, 2009 | 95 | 2009 |
| Monitoring gene therapy by external imaging of mRNA: Pilot study on murine erythropoietin J Segura, C Fillat, D Andreu, J Llop, O Millan, BG de la Torre, Z Nikolovski, ... Therapeutic drug monitoring 29 (5), 612-618, 2007 | 93 | 2007 |
